GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cash Flow from Investing

ADMA Biologics (ADMA Biologics) Cash Flow from Investing : $-5.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, ADMA Biologics spent $1.2 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.2 Mil for other investing activities. In all, ADMA Biologics spent $1.4 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


ADMA Biologics Cash Flow from Investing Historical Data

The historical data trend for ADMA Biologics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Cash Flow from Investing Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.81 -12.73 -13.51 -13.91 -4.98

ADMA Biologics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 -1.95 -0.87 -0.76 -1.41

ADMA Biologics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

ADMA Biologics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

ADMA Biologics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ADMA Biologics  (NAS:ADMA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

ADMA Biologics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-1.2 Mil. It means ADMA Biologics spent $1.2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

ADMA Biologics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

ADMA Biologics's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

ADMA Biologics's sale of business for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

ADMA Biologics's purchase of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

ADMA Biologics's sale of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

ADMA Biologics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.0 Mil. It means ADMA Biologics paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

ADMA Biologics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means ADMA Biologics paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

ADMA Biologics's cash from other investing activities for the three months ended in Dec. 2023 was $-0.2 Mil. It means ADMA Biologics paid $0.2 Mil for other investing activities.


ADMA Biologics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics (ADMA Biologics) Business Description

Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Executives
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp director, 10 percent owner 5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487